

## CURRICULUM VITAE

**Luke T. Nordquist, M.D., F.A.C.P.**  
**Urologic Medical Oncologist**

### **Urology Cancer Center, P.C.**

CEO

Urologic Medical Oncologist

12/2010-Present

Office : 17607 Gold Plaza, Omaha, NE 68130

### **GU Research Network, LLC** (Urologic Cancer Clinical Trials Network)

CEO

17607 Gold Plaza, Omaha, NE 68130

402-991-8468

1/2011-Present

### **CancerOpinions.com, LLC** (Nordquist Simmonds Medical Network)

CEO

17607 Gold Plaza, Omaha, NE 68130

11/2009-Present

### **Nebraska Cancer Specialists, P.C.**

The Physicians of Oncology Hematology West

Medical Oncology/Hematology (07/07/04 to 11/30/2010)

## EDUCATION

**Undergraduate:** Creighton University, Omaha, NE 08/87-05/89

**Pharmacy School:** Creighton University School of Pharmacy, Omaha, NE 08/89-05/92

**Medical School:** Creighton University School of Medicine, Omaha, NE 08/94-05/98 (M.D.)

**Internal Medicine Residency:** University of South Florida, Tampa, FL 07/98-06/01

**Oncology Hematology Fellowship:** Memorial Sloan-Kettering Cancer Center & Joan & Sanford I. Weill Medical College of Cornell University, New York, NY 07/01-05/04

## BOARD CERTIFICATION

American Board of Internal Medicine

American Board of Internal Medicine – Medical Oncology

## ACADEMIC POSITION

Creighton University: Associate Professor, Department of Internal Medicine, Hematology/Oncology Section

## TEACHING ACTIVITIES

Mentor of Pre-medicine students 2008-Present

## COMMUNITY PARTICIPATION



Radio Host of “CancerOpinions with Dr. Luke” a weekly radio show to educate the public about cancer topics including the diagnosis, biology, treatment, research, and healthcare reform.



Founder and Chairman of “Your Team” a nonprofit organization developed to assist cancer patients and their families with their daily needs and personal requests through our volunteer army. 2009-Present



Founder and Chairman of “Livestrong Omaha” a nonprofit organization developed to raise support and awareness for the Lance Armstrong Foundation (LAF) to benefit cancer patients. We raised more than \$62,000 for the LAF from 2007-2008.

KWAA Little League Baseball Coach 4-5 year olds

#### **PROFESSIONAL MEMBERSHIPS**

American College of Physicians/American Society of Internal Medicine	Since 1998
American Society of Clinical Oncology	Since 2002
American Medical Association	
Nebraska Oncology Society	
Nebraska Medical Association	

#### **CLINICAL PRACTICE, INTERESTS, AND ACCOMPLISHMENTS**

Member of the American Society of Clinical Oncology Government Relations Committee.

1 on 12 Oncologists chosen for ASCO Leadership Development Program 2010-2011.

President and Founder of “Canceropinions.com” an online oncology service for patients to receive expert second opinions

Cadre Committee Member of Cancer and Leukemia Group B (CALGB) Genitourinary Tumors 2008-Present

#### **CLINICAL PRACTICE, INTERESTS, AND ACCOMPLISHMENTS (Cont.)**

Member of the American Society of Clinical Oncology (ASCO) Expert Panel for the Development of Guidelines for Metastatic Non-Small Cell Lung Cancer 2008-2009

Member of the American Society of Clinical Oncology (ASCO) Expert Panel for the Development of Guidelines for Advanced Prostate Cancer 2011-Present

Medical Executive Board Alegent Health Lakeside Hospital: Elected to a 6 year term consisting of:

2008-2010: Secretary Treasurer

2010-2012: Vice Chief of Staff

2012-2014: Chief of Staff

Member of Alegent Health System Credentialing Board 2008-Present

Member of Alegent Health Lakeside Hospital Credentialing Board 2008-Present

Member of Alegant Health Lakeside Hospital Physician Excellence Committee 2008-Present

Member of Alegant Health Clinical Practice Committee 2010-Present

Member of Alegant Health Physician Collaboration Committee 2010-Present

- Purpose to create a model for a pluralistic medical staff comprised of both employed and independent physicians with a share purpose, defined expectations and mutual accountability.

Group Recipient of the 2009 ASCO Clinical Trials Participation Award. One of 8 sites in the U.S.

Group Recipient of the 2009 ASCO Community Oncology Research Grant. One of 2 sites in the U.S.

Current Health Care Affiliations/Clinical Privileges:

- 1) Alegant Health System
  - Bergan Mercy Medical Center – Active
  - Lakeside Hospital – Active
  - Immanuel Medical Center – Associate
  - Midlands Community Hospital – Active
- 2) Creighton University Medical Center – Associate Professor
- 3) Methodist Hospital – Active
- 4) Nebraska Medical Center - Consulting
  - Clarkson Hospital
  - University of Nebraska Medical Center

## RESEARCH EXPERIENCE

Cadre Committee Member of Cancer and Leukemia Group B (CALGB) Genitourinary Tumors Core Committee 2008-Present

Local Principal Investigator for several Genitourinary Clinical Trials- Present

- 1) A Randomized, Placebo-Controlled, Double – Blinded, Phase 3 Study Evaluating the Pain Palliation Benefit of Adding Custirsen to a Taxane for Second-line Chemotherapy in Men with Castrate Resistant Prostate Cancer
- 2) An Open Label Study of Abiraterone Acetate in Subjects with Metastatic Castration-Resistant Prostate Cancer Who Have Progressed After Taxane-Based Chemotherapy
- 3) A Registry of Sipuleucel-T Therapy in Men with Advanced Prostate Cancer
- 4) A Phase 3, Randomized, Double-blind, Multicenter Trial Comparing TAK-700 plus Prednisone with Placebo plus Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer **Protocol No. C21004**
- 5) A Phase 3, Randomized, Double-blind, Multicenter Trial Comparing TAK-700 plus Prednisone with Placebo plus Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer that has Progressed During or Following Docetaxel-based Therapy **Protocol No. C21005**
- 6) A Randomized, Open Label, Multicenter, Phase III, 2-Arm Study of Androgen Deprivation with Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Subjects with a Rising PSA Following Definitive Local Therapy
- 7) A Randomized Phase II study of Intermittent Chemotherapy or Intermittent Chemotherapy with Maintenance GM-CSF in Patients with Previously Untreated Metastatic Hormone Refractory Prostate Cancer
- 8) Cougar 301 - Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy
- 9) Cougar 302 - A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancer Subjects with a Rising PSA Following Definitive Local Therapy

**Memorial Sloan Kettering Cancer Center****Division of Genitourinary Oncology**

Faculty Physicians: Scher, Howard M.D. 2002 – 2004

- 1) Vaccination of Prostate Cancer Patients with Human and Mouse Prostate Specific Membrane Antigen DNA Vaccines:  
A phase I trial to assess safety and immune response: MSKK IRB #00-133
- 2) Rapid Hormonal Cycling as Treatment for Patients with Prostate Cancer: The MEN'S Cycle: MSKCC IRB #01-085
- 3) Rapid Hormonal Cycling as with Docetaxel as a Treatment for Patients with Hormonal Sensitive Prostate Cancer

**H. Lee Moffitt Cancer Center****Division of Thoracic Oncology**

Faculty Physician: Simon, George MD 2000 – 2001

- 1) A Retrospective Study Comparing Survival Outcomes in Smokers vs. Never-Smokers with Adenocarcinoma of the Lung

**Creighton University Allergy Disease Center**

Faculty Physician: Townley, RG. MD 1995 – 1996

- 1) Comparison of Hypertonic Saline to Methacholine Bronchoprovocation Challenges in Selected Subjects

**Creighton University Department of Pharmacology and Toxicology**

Faculty: Stohs, S PhD, Roche, V PhD 1990 - 1991

- 1) Glutathione Monoethyl Esters and Their Role in Preventing Lipid Peroxidation in the Liver
- 2) D-glycosylamines with Derivatives of Glucose and Galactose to Form a Safe and Effective Antidote for Ricin Poisoning

**SELECTED PUBLICATIONS**

Azzoli CG, Temin S, Aliff T, Baker S Jr, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, **Nordquist L**, Pao W, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G. 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Clin Oncol, 2011.

Scher, HI, Jia X, Chi K, deWit R, Berry W, Albers P, Henick B, Waterhouse D, Ruether D, Rosen P, Meluch A, **Nordquist L**, Venner P, Heidenreich A, Heller G. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.

Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, **Nordquist L**, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G. "American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small Cell Lung Cancer," Journal Clinical Oncology Dec 2009.

**Nordquist L**, Scher H, Slovin S, Wolchok J. A Review of Gene Therapy in Prostate Cancer. Sem. In Oncology, 2003.

**Nordquist L**, Saba H, Moscinski L. IgM Myeloma: An IgM Gammopathy Distinct from Waldenstrom's Macroglobulinemia. Hematology 2001; 6 (1): 53-58

**Nordquist L**, Wallach P. Letter: Oxetotide for Gastrointestinal Bleeding of Obscure Origin in an anticoagulated Patient. Digestive Diseases and Sciences; 47 (7): 1514 – 1515, July 2002.

Feltquate D., **Nordquist L.**, Eicher C., Morris M., Smaletz O., Slovin S., Curley T., Wilton A., Fleisher M., Heller G., Scher H. I. Rapid Androgen Cycling as Treatment for Patients with Prostate Cancer, Clin Cancer Res, 2006 Dec 15;12(24):7414-21, PMID:17189414 (PubMed – Indexed for MEDLINE)

Wolchok JD, Gregor PD, **Nordquist LT**, Slovin SF, Scher HI DNA Vaccines: An active Immunization Strategy for Prostate Cancer Semin Oncol. 2003 Oct 30(5);659-66 Review. PMID: 14571413 (PubMed – Indexed for MEDLINE)

**Nordquist, L.** Case report/Discussion: A 29 Year Old Man with Pulmonary Nodules. Hematology and Oncology Pearls 2005, pgs 165-167.

**Nordquist, L.** Case report/Discussion: A 59 Year Old Woman with Hematuria. Hematology and Oncology Pearls 2005, pgs 161-164.

## **SELECTED PRESENTATIONS**

Provenge Vaccine for Advanced Prostate Cancer: 12/2010-9/2011: San Francisco, CA; Houston, TX; Seattle, WA; Sioux Falls, SD; Springfield, MO, Kansas City, MO

Advancements in the management of Prostate Cancer : 2009: Nebraska Urologic Society.

Panel Discussant for Oncology Opportunities in the Community: American Society of Clinical Oncology (ASCO) Meeting Orlando, FL. June 2009

Midwest ASCO Highlights Conference: Genitourinary Tumor Update. Omaha, NE 2008

Midwest ASCO Highlights Conference: Genitourinary Tumor Update. Omaha, NE 2004

Rapid Hormonal Cycling as a Treatment for Patients with Prostate Cancer: The MEN'S Cycle, Poster Session , American Society of Clinical Oncology, 2003. Orlando, FL

Improved Survival in Never Smokers versus Current Smokers with Primary Adenocarcinoma of the Lung. Poster Session, American Society of Clinical Oncology, 2002. Orlando, FL